Dynavax Technologies Corporation (NASDAQ: DVAX) stock jumped 1.73% on Friday to $14.13 against a previous-day closing price of $13.89. With 1.29 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.88 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $14.50 whereas the lowest price it dropped to was $13.95. The 52-week range on DVAX shows that it touched its highest point at $21.39 and its lowest point at $7.26 during that stretch. It currently has a 1-year price target of $25.75. Beta for the stock currently stands at 1.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DVAX was down-trending over the past week, with a drop of -3.94%, but this was up by 0.78% over a month. Three-month performance surged to 54.43% while six-month performance rose 11.70%. The stock gained 45.07% in the past year, while it has gained 0.43% so far this year. A look at the trailing 12-month EPS for DVAX yields 0.52 with Next year EPS estimates of 0.70. For the next quarter, that number is 0.22. This implies an EPS growth rate of 172.60% for this year and -37.20% for next year.
Float and Shares Shorts:
At present, 124.56 million DVAX shares are outstanding with a float of 116.23 million shares on hand for trading. On Jul 14, 2022, short shares totaled 19.38 million, which was 15.34% higher than short shares on Jun 14, 2022. In addition to Mr. Ryan Spencer as the firm’s CEO & Director, Mr. David F. Novack serves as its Pres & COO.
Through their ownership of 82.56% of DVAX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold — of DVAX, in contrast to — held by mutual funds. Shares owned by individuals account for –. With a 6.56% stake in DVAX, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 8,283,580 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Fund, which owns about 6.55% of DVAX stock, is the second-largest Mutual Fund holder. It holds 8,274,643 shares valued at 104.18 million. Federated Hermes Kaufmann Small C holds 6.29% of the stake in DVAX, owning 7,942,500 shares worth 100.0 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DVAX since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DVAX analysts setting a high price target of $30.00 and a low target of $20.00, the average target price over the next 12 months is $25.75. Based on these targets, DVAX could surge 112.31% to reach the target high and rise by 41.54% to reach the target low. Reaching the average price target will result in a growth of 82.24% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. DVAX will report FY 2022 earnings on 03/14/2023. Analysts have provided yearly estimates in a range of $1.20 being high and $1.00 being low. For DVAX, this leads to a yearly average estimate of $1.11. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Dynavax Technologies Corporation surprised analysts by -$0.06 when it reported $0.22 EPS against a consensus estimate of $0.28. The surprise factor in the prior quarter was -$0.09. Based on analyst estimates, the high estimate for the next quarter is $0.25 and the low estimate is $0.21. The average estimate for the next quarter is thus $0.23.
Summary of Insider Activity:
Insiders traded DVAX stock several times over the past three months with 1 Buys and 1 Sells. In these transactions, 6,000 shares were bought while 6,000 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 24 over the past year. The total number of shares bought during that period was 2,334,178 while 2,464,169 shares were sold.